mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The present study investigated the dynamics and prognostic role of messenger RNA (mRNA) expression responsible for18F-fluorodeoxyglucose (FDG) uptake in FDG positron emission tomography (PET) and radioactive iodine (131I) uptake in wholebodyradioactive iodine scans (WBS) in papillary thyroid cancer (PTC) patients. Materials and Methods: The primary and processed data were downloaded from the Genomic Data Commons Data Portal. Expressiondata for sodium/iodide symporter (solute carrier family 5 member 5, SLC5A5), hexokinase (HK1–3), glucose-6-phosphatedehydrogenase (G6PD), and glucose transporter (solute carrier family 2, SLC2A1–4) mRNA were collected. Results: Expression of SLC5A5 mRNA were negatively correlated with SLC2A1 mRNA and positively correlated with SLC2A4mRNA. In PTC with BRAF mutations, expressions of SLC2A1, SLC2A3, HK2, and HK3 mRNA were higher than those in PTC withoutBRAF mutations. Expression of SLC5A5, SLC2A4, HK1, and G6PD mRNA was lower in PTC without BRAF mutation. PTCswith higher expression of SLC5A5 mRNA had more favorable disease-free survival, but no association with overall survival. Conclusion: Expression of SLC5A5 mRNA was negatively correlated with SLC2A1 mRNA. This finding provides a molecular basisfor the management of PTC with negative WBS using 18F-FDG PET scans. In addition, higher expression of SLC5A5 mRNA wasassociated with less PTC recurrence, but not with deaths.
Abstract
Purpose: The present study investigated the dynamics and prognostic role of messenger RNA (mRNA) expression responsible for18F-fluorodeoxyglucose (FDG) uptake in FDG positron emission tomography (PET) and radioactive iodine (131I) uptake in wholebodyradioactive iodine scans (WBS) in papillary thyroid cancer (PTC) patients. Materials and Methods: The primary and processed data were downloaded from the Genomic Data Commons Data Portal. Expressiondata for sodium/iodide symporter (solute carrier family 5 member 5, SLC5A5), hexokinase (HK1–3), glucose-6-phosphatedehydrogenase (G6PD), and glucose transporter (solute carrier family 2, SLC2A1–4) mRNA were collected. Results: Expression of SLC5A5 mRNA were negatively correlated with SLC2A1 mRNA and positively correlated with SLC2A4mRNA. In PTC with BRAF mutations, expressions of SLC2A1, SLC2A3, HK2, and HK3 mRNA were higher than those in PTC withoutBRAF mutations. Expression of SLC5A5, SLC2A4, HK1, and G6PD mRNA was lower in PTC without BRAF mutation. PTCswith higher expression of SLC5A5 mRNA had more favorable disease-free survival, but no association with overall survival. Conclusion: Expression of SLC5A5 mRNA was negatively correlated with SLC2A1 mRNA. This finding provides a molecular basisfor the management of PTC with negative WBS using 18F-FDG PET scans. In addition, higher expression of SLC5A5 mRNA wasassociated with less PTC recurrence, but not with deaths.
참고문헌 (26)
- Cabanillas ME, "Thyroid cancer", Lancet, 388, pp.2783~2795 (2016)[DOI]
- Ahn HS, "South Korea's thyroid-cancer "Epidemic"--turning the tide", N Engl J Med, 373, pp.2389~2390 (2015)[DOI]
- Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26, pp.1~133 (2016)[DOI]
- Pak K, "Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and metaanalysis", J Nucl Med, 55, pp.884~890 (2014)[DOI]
- Tavares C, "ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome", Eur J Endocrinol, 174, pp.R117~R126 (2016)[DOI]
- Chai YJ, "Upregulation of SLC2 (GLUT) family genes is related to poor survival outcomes in papillary thyroid carcinoma: analysis of data from The Cancer Genome Atlas", Surgery, 161, pp.188~194 (2017)[DOI]
- Smith TA, "FDG uptake, tumour characteristics and response to therapy: a review", Nucl Med Commun, 19, pp.97~105 (1998)[DOI]
- Filetti S, "Sodium", iodide symporter: a key transport system in thyroid cancer cell metabolism, 1999, pp.141, 443~457
- Cancer Genome Atlas Research Network, "Integrated genomic characterization of papillary thyroid carcinoma", Cell, 159, pp.676~690 (2014)[DOI]
- Ros P, "Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis", Biochimie, 81, pp.389~396 (1999)[DOI]
- Winter J, "Patients with high-risk differentiated thyroid cancer have a lower I-131 ablation success rate than low-risk ones in spite of a high ablation activity", Clin Endocrinol (Oxf), 85, pp.926~931 (2016)[DOI]
- Ravazoula P, "Immunohistochemical expression of glucose transporter Glut1 and cyclin D1 in breast carcinomas with negative lymph nodes", Eur J Gynaecol Oncol, 24, pp.544~546 (2003)
- Haber RS, "GLUT1 glucose transporter expression in benign and malignant thyroid nodules", Thyroid, 7, pp.363~367 (1997)[DOI]
- Jozwiak P, "Expression of hypoxia-related glucose transporters GLUT1 and GLUT3 in benign, malignant and non-neoplastic thyroid lesions", Mol Med Rep, 6, pp.601~606 (2012)[DOI]
- 김성은, "Expression Patterns of Glucose Transporter-1 Gene and Thyroid Specific Genes in Human Papillary Thyroid Carcinoma", Nuclear Medicine and Molecular Imaging, 48(2), pp.91~97 (2014), 대한핵의학회
- Chung JK, "Sodium iodide symporter: its role in nuclear medicine", J Nucl Med, 43, pp.1188~1200 (2002)
- Moon SH, "Comparison of 18F-fluorodeoxyglucose uptake with the expressions of glucose transporter type 1 and Na+", I- symporter in patients with untreated papillary thyroid carcinoma, 2013, pp.38, 77~84
- Chung JK, "Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan", J Nucl Med, 40, pp.986~992 (1999)
- Morari EC, "Use of sodium iodide symporter expression in differentiated thyroid carcinomas", Clin Endocrinol (Oxf), 75, pp.247~254 (2011)[DOI]
- Yamamoto T, "Over-expression of facilitative glucose transporter genes in human cancer", Biochem Biophys Res Commun, 170, pp.223~230 (1990)[DOI]
- Pak K, "Prognostic value of genetic mutations in thyroid cancer: a meta-analysis", Thyroid, 25, pp.63~70 (2015)[DOI]
- 서성환, "Prognostic Value of Extranodal Extension in Thyroid Cancer: A Meta-Analysis", Yonsei Medical Journal, 57(6), pp.1324~1328 (2016), 연세대학교의과대학[DOI]
- Ward LS, "Low expression of sodium iodide symporter identifies aggressive thyroid tumors", Cancer Lett, 200, pp.85~91 (2003)[DOI]
- Schlumberger MJ, "Papillary and follicular thyroid carcinoma", N Engl J Med, 338, pp.297~306 (1998)[DOI]
- Ulanovskaya OA, "A pairwise chemical genetic screen identifies new inhibitors of glucose transport", Chem Biol, 18, pp.222~230 (2011)[DOI]
- Kogai T, "The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics", Pharmacol Ther, 135, pp.355~370 (2012)[DOI]